Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer

被引：0
|
作者：
Bauer, Smadar
Saad, Akram
Greenhouse, Inbal
Rapoport, Anna Ruth
Shahar, Shir
Barnatan, Tania
Satchi-Fainaro, Ronit
Shapira-Frommer, Ronnie
机构：
[1] Sheba Med Ctr, Ramat Gan, Israel
[2] Tel Aviv Univ, Dept Physiol & Pharmacol, Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5581
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer
    Benigno, B. B.
    Burrell, M. O.
    Daugherty, P.
    Hernandez, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study
    Zivanovic, Oliver
    Chi, Dennis S.
    Zhou, Qin
    Iasonos, Alexia
    Konner, Jason A.
    Makker, Vicky
    Grisham, Rachel N.
    Brown, Amy K.
    Nerenstone, Stacy
    Diaz, John P.
    Schroeder, Eric D.
    Langstraat, Carrie L.
    Paroder, Viktoriya
    Lakhman, Yulia
    Soldan, Krysten
    Su, Katy
    Gardner, Ginger J.
    Andikyan, Vaagn
    Guo, Jianxia
    Jewell, Elizabeth L.
    Roche, Kara Long
    Troso-Sandoval, Tiffany
    Lichtman, Stuart M.
    Moukarzel, Lea A.
    Dessources, Kimberly
    Abu-Rustum, Nadeem R.
    Aghajanian, Carol
    Tew, William P.
    Beumer, Jan
    Sonoda, Yukio
    O'Cearbhaill, Roisin E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (23) : 2594 - +
  • [43] CARBOPLATIN (CBDCA) PLUS LIPOSOMAL DOXORUBICIN (LD) IN PLATINUM SENSITIVE OVARIAN CANCER: A PHASE II STUDY
    Cianci, Claudia
    Di Donato, Samantha
    Gadducci, Angiolo
    Cosio, Stefania
    Pastina, Ilaria
    Fanucchi, Antonio
    Orlandini, Cinzia
    Ricci, Sergio
    ANNALS OF ONCOLOGY, 2004, 15 : 95 - 95
  • [44] Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.
    Vogelzang, Nicholas J.
    Encarnacion, Carlos A.
    Cohn, Allen Lee
    DiSimone, Christopher
    Rasco, Drew W.
    Richards, Donald A.
    Taylor, Matthew H.
    Dutcus, Corina E.
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Guo, Matthew
    Schmidt, Emmett V.
    Mier, James Walter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [45] Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer
    Rapoport, B. L.
    Vorobiof, D. A.
    Slabber, C.
    Alberts, A. S.
    Hlophe, H. S.
    Mohammed, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (06) : 1137 - 1141
  • [46] A phase II study of chemoimmunotherapy for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancers
    Schmeler, K. M.
    Vadhan-Raj, S.
    Ramirez, P. T.
    Cohen, L.
    Garcia, M. E.
    Bassett, R. I.
    Iyer, R. B.
    Mueller, P.
    Levenback, C. L.
    Wolf, J. K.
    Gershenson, D. M.
    Freedman, R. S.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S112 - S112
  • [47] The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
    Gubbi, Ajit
    Kendrick, James E.
    Finkler, Neil J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (10) : 1105 - 1113
  • [48] PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB FOR LEPTOMENINGEAL METASTASES
    Wang, Nancy
    Gerstner, Elizabeth
    Cahill, Daniel
    Oh, Kevin
    Cahill, Jennifer
    Brastianos, Priscilla
    NEURO-ONCOLOGY, 2021, 23 : 48 - 49
  • [49] Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.
    Wenham, Robert Michael
    Apte, Sachin M.
    Shahzad, Mian M.
    Lee, Jae K.
    Dorman, Denise
    Chon, Hye Sook
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] NEOplus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma
    Mao, L.
    Bai, X.
    Wei, X.
    Dai, J.
    Cui, C-L.
    Chi, Z.
    Sheng, X.
    Lian, B.
    Wang, X.
    Bixia, T.
    Si, L.
    Guo, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S951 - S951
12345